Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.60 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.48 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398871 | 0.97 | LTB4R2 (0.56) | LTB4R2LPAR1HDAC1HDAC6LIMK1 | |
| SCHEMBL5404377 | 0.95 | LTB4R2 (0.60) | LTB4R2LPAR1HDAC1HDAC6LIMK1 | |
| SCHEMBL5405911 | 0.92 | TSHR (0.55) | LTB4R2LPAR1 | |
| SCHEMBL5412103 | 0.92 | LTB4R2 (0.54) | LTB4R2LPAR1HDAC1HDAC6PKM | |
| SCHEMBL5408998 | 0.91 | LTB4R2 (0.51) | LTB4R2LPAR1HDAC1HDAC6LIMK1 | |
| SCHEMBL5394630 | 0.90 | LPAR1 (0.53) | LTB4R2LPAR1LIMK2 | |
| SCHEMBL5414113 | 0.89 | LPAR1 (0.58) | LTB4R2LPAR1HDAC1HDAC6HDAC3 | |
| SCHEMBL5402609 | 0.89 | LPAR1 (0.59) | LTB4R2LPAR1 | |
| SCHEMBL5399607 | 0.89 | LTB4R2 (0.56) | LTB4R2LPAR1HDAC1HDAC6LIMK1 | |
| SCHEMBL5401137 | 0.88 | LTB4R2 (0.49) | LTB4R2LPAR1HDAC1HDAC6LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | LTB4R2 329/4885LPAR1 17/4885HDAC1 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.